GSA Capital Partners’s Vor Biopharma VOR Stock Holding History

GSA Capital Partners’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-593	Closed	-$9K	–	2179
2025 Q1	$9K	Buy	+593	New	+$14.2K	﹤0.01%	1593

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's VOR Position: Q2 2025 in Review

GSA Capital Partners sold out of Vor Biopharma (VOR) in Q2 2025, closing a stake of 593 shares — an estimated $9K sold.

GSA Capital Partners first reported a position in VOR in Q1 2025 and held it in 1 quarter. The position peaked at $9K in Q1 2025. 35 funds tracked by Wall St. Rank hold VOR as of Q2 2025.

GSA Capital Partners reported no remaining Vor Biopharma position as of Q2 2025 after selling out during the quarter.
GSA Capital Partners sold 593 Vor Biopharma shares in Q2 2025, an estimated $9K.
GSA Capital Partners first reported a position in Vor Biopharma in Q1 2025 and held it in 1 quarter.
GSA Capital Partners's Vor Biopharma position peaked at $9K in Q1 2025.
35 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.